ONCO FA

Pasquale Pignatelli
Daniele Pastori

SAPIENZA
UNIVERSITÀ DI ROMA

START REGISTRY

ONCO FA

Incidenza di FA in pazienti con neoplasie

4,324,545 soggetti di cui 316,040 con neoplasie





Jakobsen et al. BMC Cancer (2019) 19:1105

5° CONVEGNO ANTICOAGULAZIONE.it

Attualità cliniche e di laboratorio. Aspetti sociali

BOLOGNA 6-7 FEBBRAIO 2020 Hotel Savoia Regency

Cancer and Atrial Fibrillation: Etiology

- Inflammatory response in neoplastic processes
- Hyperadrenergic state
- Metabolic and electrolyte derangements
- Metastatic involvement of cardiac structures
- Paraneoplastic syndromes
- Chemotherapeutic agents



Farmakis D, et al. J Am Coll Cardiol. 2014;63:945-53
ANS, autonomous nervous system

Complicanze tromboemboliche e di sanguinamento in pazienti con neoplasie e FA

N° eventi (%/anno)	ROCKET (2010)		ARISTOTLE (2010)		ENGAGE (2016)	
Neoplasia	SI	NO	SI	NO	SI	NO
ICTUS ISCHEMICO	12 (2.03)	196 (1.62)	9 (0.8)	166 (1.1)	21 (2.08)	214 (2.08)
SANGUINAMENTO MAGGIORE E NMCR	96 (21.59)	1353 (14.19)	67 (6.9)	810 (5.9)	174 (27.94)	1636 (12.49)
SANGUINAMENTO MAGGIORE	33 (6.44)	353 (3.31)	32 (3.2)	430 (3.1)	63 (8.18)	494 (3.34)
TUTTI I SANGUINAMENTI (MAGGIORI, NMCR, MINORI)	152 (40.79)	2132 (24.97)	245 (32.2)	2815 (25.4)	195 (33.82)	1969 (15.77)

Real life

- In 2,568 consecutive AF patients with newly diagnosed cancer, stroke/systemic embolism (SE), major bleeding, and all-cause death were analysed.
- NOACs have significantly lower incidences of ischemic stroke/systemic embolism (p<0.001), major bleeding (p<0.001), and all-cause death (p<0.001) than warfarin
  - The incidence of major bleeding was particularly lower within 1 year after cancer diagnosis
  - The incidences of all clinical events were significantly lower in the NOAC group vs warfarin group



Kim et al. Korean Circ J. 2018;48:406–17.

DOACs in cancer and AF

MarketScan databases, we identified 16 096 AF patients (mean age, 74 years) initiating oral anticoagulant and being actively treated for cancer



blood advances 13 FEBRUARY 2018 · VOLUME 2, NUMBER 3 DIRECT ORAL ANTICOAGULANTS VS WARFARIN IN CANC

SHAH et al 13 FEBRUARY 2018 x VOLUME 2, NUMBER 3 DOI 10.1182/bloodadvances.2017010694.

Drug-Drug Interactions of NOACs in Cancer Patient



Obiettivi

- Ricercare evidenze cliniche sulle interazioni farmacologiche
- Valutare efficacia e sicurezza dei diversi trattamenti anticoagulanti
- Migliorare le conoscenze nella gestione del paziente affetto da FA e cancro